Acquired by The Column Group LP in Apr 2024
NGM - NGM Biopharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
NGM price evolution
NGM
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $61.27 | $56.93 | $57.23 | $71.5 |
| Short term investments | $88.37 | $114.57 | $140.27 | $163.46 |
| Net receivables | $0.06 | $0.74 | $1.26 | |
| Inventory | ||||
| Total current assets | $156.44 | $177.04 | $204.4 | $242.53 |
| Long term investments | ||||
| Property, plant & equipment | $7.03 | $7.82 | $8.83 | $9.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.42 | $15.11 | $16.14 | $16.31 |
| Total investments | $88.37 | $114.57 | $140.27 | $163.46 |
| Total assets | $168.87 | $192.15 | $220.54 | $258.84 |
| Current liabilities | ||||
| Accounts payable | $2.98 | $4.69 | $5.86 | $13.29 |
| Deferred revenue | $0.11 | $0.69 | $0.38 | |
| Short long term debt | $1.38 | $2.75 | $4.07 | |
| Total current liabilities | $20.08 | $22.34 | $28.42 | $37.9 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.15 | |||
| Total debt | $1.38 | $2.75 | $4.07 | |
| Total liabilities | $20.23 | $22.34 | $28.42 | $37.9 |
| Shareholders' equity | ||||
| Retained earnings | -$724.01 | -$696.34 | -$667.54 | -$629.28 |
| Other shareholder equity | $0.02 | -$0.08 | -$0.15 | -$0.1 |
| Total shareholder equity | $148.64 | $169.81 | $192.12 | $220.93 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $61.27 | $77.41 | $153.29 | $148.52 |
| Short term investments | $88.37 | $198.04 | $214.46 | $148.14 |
| Net receivables | $0.06 | $7.58 | $4.95 | $0.33 |
| Inventory | ||||
| Total current assets | $156.44 | $288.86 | $379.28 | $308.43 |
| Long term investments | ||||
| Property, plant & equipment | $7.03 | $10.59 | $14.12 | $14.53 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.42 | $18.54 | $23.11 | $20.62 |
| Total investments | $88.37 | $198.04 | $214.46 | $148.14 |
| Total assets | $168.87 | $307.4 | $402.39 | $329.04 |
| Current liabilities | ||||
| Accounts payable | $2.98 | $8.45 | $5.25 | $9.66 |
| Deferred revenue | $0.37 | $17.77 | $2.98 | |
| Short long term debt | $5.38 | $5.08 | ||
| Total current liabilities | $20.08 | $47.84 | $61.35 | $42.58 |
| Long term debt | $5.38 | |||
| Total noncurrent liabilities | $0.15 | $5.38 | $6.42 | |
| Total debt | $5.38 | $10.46 | ||
| Total liabilities | $20.23 | $47.84 | $66.74 | $49 |
| Shareholders' equity | ||||
| Retained earnings | -$724.01 | -$581.63 | -$418.97 | -$298.63 |
| Other shareholder equity | $0.02 | -$0.3 | -$0.13 | $0 |
| Total shareholder equity | $148.64 | $259.56 | $335.65 | $280.04 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $21.89 | $22.94 | $32.35 | $40.86 |
| Selling, general & administrative | $7.94 | $8.67 | $9.65 | $11.58 |
| Total operating expenses | $29.83 | $31.61 | $42 | $52.44 |
| Operating income | -$29.83 | -$31.61 | -$42 | -$52.44 |
| Income from continuing operations | ||||
| EBIT | -$27.67 | -$28.8 | -$38.26 | -$47.65 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$27.67 | -$28.8 | -$38.26 | -$47.65 |
| Income (for common shares) | -$27.67 | -$28.8 | -$38.26 | -$47.65 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $118.04 | $181.07 | $161.71 | $163.97 |
| Selling, general & administrative | $37.84 | $40.52 | $36.87 | $27.23 |
| Total operating expenses | $155.88 | $221.58 | $198.58 | $191.2 |
| Operating income | -$155.88 | -$221.58 | -$198.58 | -$191.2 |
| Income from continuing operations | ||||
| EBIT | -$142.38 | -$162.67 | -$120.33 | -$102.49 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$142.38 | -$162.67 | -$120.33 | -$102.49 |
| Income (for common shares) | -$142.38 | -$162.67 | -$120.33 | -$102.49 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$27.67 | -$28.8 | -$38.26 | -$47.65 |
| Operating activities | ||||
| Depreciation | $1.06 | $1.06 | $1.08 | $1.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.3 | $6.41 | $7.48 | $8.54 |
| Total cash flows from operations | -$22.96 | -$27.16 | -$40.25 | -$41.83 |
| Investing activities | ||||
| Capital expenditures | -$0.19 | -$0.29 | -$0.1 | -$0.67 |
| Investments | $27.38 | $27.16 | $24.69 | $36.31 |
| Total cash flows from investing | $27.19 | $26.87 | $24.59 | $35.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.11 | $1.39 | $0.28 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.11 | $1.39 | $0.28 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.34 | -$0.29 | -$14.28 | -$5.91 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$142.38 | -$162.67 | -$120.33 | -$102.49 |
| Operating activities | ||||
| Depreciation | $4.32 | $5.98 | $7.9 | $6.55 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $28.72 | $32.38 | $26.24 | $15.65 |
| Total cash flows from operations | -$132.2 | -$144.44 | -$73.23 | -$83.5 |
| Investing activities | ||||
| Capital expenditures | -$1.25 | -$1.86 | -$1.68 | -$1.88 |
| Investments | $115.54 | $16.18 | -$69.97 | -$49.12 |
| Total cash flows from investing | $114.29 | $14.32 | -$71.65 | -$51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.77 | $54.23 | $149.66 | $36.15 |
| Net borrowings | ||||
| Total cash flows from financing | $1.77 | $54.23 | $149.66 | $35.54 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$16.14 | -$75.88 | $4.78 | -$98.96 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 82.91M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$138.06M |
| EBIT | -$142.38M |
| Net Income | -$142.38M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.79 |
| Cash/Share | 0.74 |
| EPS | -$1.72 |
|---|---|
| ROA | -67.77% |
| ROE | -77.85% |
| Debt/Equity | 0.14 |
|---|---|
| Net debt/EBITDA | 0.30 |
| Current ratio | 7.79 |
| Quick ratio | 7.79 |